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Abstract
Background: Adenoviruses are common pathogens infecting animals and humans. They are classified based on
serology, or genome sequence information. These methods have limitations due to lengthy procedures or lack of
infectivity data. Adenoviruses are easy to produce and amenable to genetic and biochemical modifications, which
makes them a powerful tool for biological studies, and clinical gene-delivery and vaccine applications. Antibodies
directed against adenoviral proteins are important diagnostic tools for virus identification in vivo and in vitro, and
are used to elucidate infection mechanisms, often in combination with genomic sequencing and type specific
information from hyper-variable regions of structural proteins.
Results: Here we describe a novel and readily useable method for cloning, expressing and purifying small fragments of
hyper-variable regions 1-6 of the adenoviral hexon protein. We used these polypeptides as antigens for generating
polyclonal rabbit antibodies against human adenovirus 3 (HAdV-B3), mouse adenovirus 1 (MAdV-1) and MAdV-2 hexon.
In Western immunoblots with lysates from cells infected from thirteen human and three mouse viruses, these antibodies
bound to homologous full-length hexon protein and revealed variable levels of cross-reactivity to heterologous hexons.
Results from immuno-fluorescence and electron microscopy studies indicated that HAdV-B3 and MAdV-2 hexon
antibodies recognized native forms of hexon.
Conclusions: The procedure described here can in principle be applied to any adenovirus for which genome
sequence information is available. It provides a basis for generating novel type-specific tools in diagnostics and
research, and extends beyond the commonly used anti-viral antibodies raised against purified viruses or subviral
components.
Keywords: Adenovirus, Hexon, Protein Purification, Antibodies, Immunofluorescence, Neutralization, Virus Blocking,
Immunoblotting, Electron Microscopy
Background
Adenoviruses (AdV) are ubiquitous pathogens, and
affect vertebrates, including humans, livestock and wild
animals. They undergo genetic recombination and periodic-
ally emerge in the human population, often in geographic-
ally distinct patterns [1]. Human adenoviruses (HAdV) are
comprised of ~60 types classified into seven species, A to G
based on serology and DNA genome sequence [2, 3]. The
genetic information of adenoviruses is encoded in a
double-stranded linear DNA molecule. It is imported into
the cell nucleus upon stepwise disassembly of incoming vi-
rions [4–7]. Adenovirus vectors are widely used in clinical
gene therapy, mostly in cancer treatment and vaccination
boost regimes [8], in part due to strong innate immunity
reactions due to viral danger signals [9, 10]. Since the viral
genome remains episomal throughout the infection cycle
[11], this gives rise to a robust, but transient viral gene
expression. In addition, AdV vectors are widely used in
clinical oncolytic applications due to the ease of genetic
engineering and biochemical modifications [12–15].
Most humans have been exposed to adenoviruses, and
raise neutralizing antibodies and protective cytotoxic T
cell responses [16–18]. In immune-competent individuals,
AdVs cause only mild or no symptoms, with no
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observable long-term effects on health [19]. Persistent in-
fections can occur [20] which may be caused by interferon
based anti-viral defense mechanisms [21]. Adenoviruses
can be live threatening to immune-compromised individ-
uals [21–23]. The high seroprevalence and immunogen-
icity of adenoviruses represents a considerable drawback
when using these viruses as vectors for gene therapy, as
pre-existing immunity leads to virus immune-complexes
which can lead to inflammatory reactions [13] and re-
duced treatment efficacy.
The AdV capsid is icosahedral, non-enveloped and
consists of three major structural proteins fiber, penton
base and hexon [24]. The facets of the capsid are com-
posed of 240 copies of the homotrimeric hexon protein,
while 12 copies of the fiber protein are attached to
pentameric penton protein bases on each of the vertices.
Each hexon trimer has a pseudo-hexagonal base, which
allows for close packaging within the facet, and three
tower domains that are exposed on the exterior surface
of the virion. All three major capsid proteins are
immunogenic [18, 25–28]. Occurrence of neutralizing
antibodies against fiber protein in naturally infected
individuals has been reported [18, 25, 29, 30].
Importantly, the bulk of functionally significant neu-
tralizing antibodies are directed against the hexon pro-
tein [31–33]. The serotype-specific residues recognized
by these antibodies are located in seven hyper-variable
regions (HVRs 1-7) protruding from the outer side of
the viral capsid as deduced by comprehensive alignment
of hexon sequences [34–37]. Experiments with hexon
chimeric viruses, in which the complete hexon, single or
combinations of HVRs were replaced by those of
another serotype, revealed escape of humoral immune
detection [31, 32, 38–42]. Purified trimeric native hexon
inhibited neutralization, but monomeric heat-denatured
hexon did not, suggesting that neutralizing epitopes are
complex and conformational but not linear [27, 34]. In
contrast to these findings, other groups reported gener-
ation of neutralizing antibodies using small HVR
peptides only [28, 43]. Non-neutralizing and cross-
reactive hexon antibodies with common species- and
genus-specific reactivity have been suggested to
recognize sites that are accessible on the purified hexon
but partially masked in the intact virion and outside of
the HVRs [27, 44]. Such antibodies were characterized
using complement fixation, immunodiffusion, immuno-
precipitation and immunoblot assays [45–47].
Mouse adenoviruses (MAdV) represent an attractive
model for studying viral and host factors involved in
acute and persistent infections, testing oncolytic vectors
in syngenic tumor models, and the development of anti-
viral drugs [48–53]. Like HAdVs they belong to the
genus of Mastadenoviruses. Reagents such as antibodies
against MAdV are scarce. Here we devised and tested
the use of minimal hexon fragments containing the
HVRs 1-6 for production of specific hexon antibodies.
Recombinant proteins generated in E. coli included
hexon fragments derived from MAdV-1, −2, and HAdV-
B3, −C5. Rabbit antibodies raised against MAdV-1, −2,
and HAdV-3 fragments were tested in immunoblot assays,
immunofluorescence, neutralization assays and EM for
binding to denatured and native hexon. All three hexon
antibodies recognized full-length hexon in Western im-
munoblots of lysates from infected cells, and two of three
antibodies recognized native virus protein in immuno-
fluorescence and transmission electron microscopy, but
not in neutralization assays.
Methods
Cells and viruses
All cell lines including the human lung carcinoma cell line
A549, the human cervical carcinoma cell line HeLa Ohio,
the mouse colon carcinoma CMT93 and 3T6 fibroblast
cells were grown in DMEM plus 8% FCS [15, 54, 55]. The
cell lines were routinely screened for the absence of
mycoplasma contamination. Human HAdV-C5 wt300 was
obtained from T. Shenk [56]. All other human prototype
viruses were kindly provided by the late T. Adrian
(Medizinische Hochschule Hannover, Germany) and were
verified by DNA restriction analysis [57] and in part by
hexon sequence analysis (R. Hendrickx et al., manuscript
in preparation). All human wild type viruses were ampli-
fied in A549 cells and viral titers were determined by
plaque assay using 911 cells as described previously [54].
Recombinant E1/E3-deleted HAd-B3 and HAdV-C5 vec-
tors expressing firefly luciferase were described previously
[58]. MAdV-1, −2 and −3 were kind gifts of K. Spindler
(University of Michigan, Ann Arbor, USA), S. Compton
(Yale University School of Medicine, USA) and D. Krüger
(Charité Campus Mitte, Berlin Germany), respectively,
and were amplified in CMT93 or 3T6 cells and titered by
qPCR (R. Hendrickx et al., manuscript in preparation).
The replication-competent HAdV-B3-pIX-FS2A-eGFP
contains an eGFP open reading frame (ORF) genetically
fused to the downstream end of the pIX gene using an
autocleavage FS2A sequence ([51] and L. Studer manu-
script in preparation). Similarly, the replication-competent
MAdV-1-E1A-FS2A-GL contains a Gaussia luciferase
(GL) ORF genetically fused to the downstream end of the
E1A gene (R. Hendrickx, manuscript in preparation). The
MAdV2-ΔE1A-eGFP contains an E1A exon 1 deletion
which was replaced by an eGFP cassette (R. Hendrickx,
manuscript in preparation).
Construction of adenoviral hexon fragment expression
vectors
For production of the four different hexon fragments the
expression vector pGEX-6P-1 vector (GE Healthcare)
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was used. DNA fragments containing the hexon HVRs
1-6 were PCR-amplified using viral genomic DNA as
template and inserted into the EcoRI and SalI cloning
sites of pGEX-6P-1. The oligonucleotide sequences
(Microsynth AG, Switzerland) used for cloning are listed
in STab 1. Hexon HVRs 1-6 protein sequences, and rela-
tive molecular sizes of the GST-hexon and final hexon
fragments are summarized in Additional file 1: Figure S1
and Additional file 2: Table S1.
Purification of adenoviral hexon protein fragments,
production of rabbit polyclonal antibodies
Five grams of cell paste corresponding to a 4-l culture of
E.coli BL21-CodonPlus(DE3)-RIPL cells, induced at 30 °C
for 4 h with 0.3 mM IPTG, were resuspended in 25 ml of
buffer T + 300 mM KCl (25 mM Tris-HCl, 10% glycerol,
protease inhibitors (aprotinin, leupeptin, pepstatin A,
PMSF), 0.5 mM EDTA, 1 mM dithiothreitol, 0.01%
Nonidet-P40, pH 7.5). The cells were then disrupted by
sonication and the lysate was clarified using ultracentrifu-
gation (45 min, 4 °C, 100,000 × g).
The lysate was incubated with 1 ml of Glutathione-
Sepharose beads (GE Healthcare) equilibrated with buf-
fer T + 300 mM KCl for 1 h at 4 °C. The beads were
then spun down and washed twice with 10 ml of
T + 300 mM KCl and once with T + 50 mM KCl,
followed by repeated protein elution with 1.5 ml of
T + 100 mM KCl containing 30 mM glutathione. Frac-
tions were analyzed by SDS-PAGE, pooled and treated
with 100 units of PreScission Protease (GE Healthcare)
for 22 h at 4 °C.
The solution was diluted with buffer 1xT until con-
ductivity reached T + 50 mM KCl and was loaded on a
1 ml Mono Q column (GE Healthcare) equilibrated in
T + 50 mM KCl. The protein was eluted using an 8 ml
gradient of 50 – 500 mM KCl in buffer T.
Peak fractions were pooled, and loaded on a 5 ml Q5
Bio-Scale column (Bio-Rad) equilibrated in T + 50 mM
KCl following adjustment of conductivity. The protein
was eluted using a 100 ml gradient of 50 – 600 mM KCl
in buffer 1xT. The elution times varied between different
fragments but under these conditions, all of the frag-
ments bound to the column, with HAdV-B3 eluting be-
tween 150 and 210 mM KCl, HAdV-C5 eluting between
270 and 350 mM KCl, MAdV-1 eluting between 90 and
130 mM KCl and MAdV-2 eluting between 60 and
110 mM KCl. Peak fractions were analyzed by SDS-
PAGE, pooled and briefly incubated with a small amount
of Glutathione-Sepharose beads to bind residual GST.
The proteins were then concentrated using a 15 ml
Vivaspin Turbo 15 concentration column with 10 kDa
cut-off (Sartorius Stedim Biotech). All purification steps
were performed at 4 °C and the final purified proteins
were stored in buffer x at −80 °C until further use.
Purified hexon HVRs 1-6 fragments were used to
immunize rabbits. Antibody development was carried
out at BioGenes GmbH (Berlin, Germany). The animals
were intramuscularly immunized using BioGenes’ adju-
vant. The adjuvant was mixed 3:1 with the antigen.
Final bleeds were done following four immunizations.
The obtained sera were mixed with Thimerosal at
0.02% as preservative.
Neutralization assay
The in vitro neutralization assay was performed as de-
scribed in [59]. In brief, 2.5 × 104 cells (3T6 for mouse
viruses, A549 for human viruses) were seeded in 100 μl
DMEM-FCS medium in 96 well plates and grown over-
night at 37 °C. Serial five-fold dilutions or fixed dilutions
of the hexon neutralizing antibody were prepared in
50 μl DMEM-FCS medium and mixed with 25 μl of
either medium or increasing amounts of the hexon
protein fragment. The mixes were incubated for 30 min
at 37 °C. Subsequently, 25 μl of the reporter virus were
added to the solutions and the mixes were incubated for
another 30 min. Positive controls omitting the antibody
and negative controls omitting the virus were included.
The virus concentration was adjusted to a multiplicity of
infection (MOI) of 5 in the case of the human viruses,
whereas for MAdV-1-E1A-FS2A-GL 103 genome equiva-
lent virus particles (geq vp) per cell were used. The
solutions were subsequently added to the cells and incu-
bated for 24 h at 37 °C. For measuring the luminescence
signal, the medium was aspirated and replaced with
40 μl of SteadyGLO lysis / substrate (Promega). The
plates were incubated for 10 min at room temperature
with orbital shaking. Then, 20 μl from each well was
transferred to a Greiner LumiTrac plate and analyzed
using a Tecan Plate reader with luminescence unit.
When using MAdV-1-E1A-FS2A-GL, the renilla lucifer-
ase assay system (Promega) was used containing the
coelenterazin substrate. All tests were performed in
triplicates and repeated twice. The dog HAdV-C5 neu-
tralizing serum was kindly provided by Anja Ehrhardt
[60, 61]. The hyperimmune rabbit anti-HAdV-B3 was a
kind gift from A. Kajon (Lovelace Respiratory Program,
Albuquerque, USA).
PAGE and western blot
For analysis of viral proteins derived from infected cells,
cells were lysed in NETN (10 mM Tris pH 8.0, 200 mM
NaCl, 1 mM EDTA, 0.5% NP40) complemented with
protease inhibitors (Mini-Complete, Roche). Analyses of
cleared cell lysates and hexon fragments from bacteria
were performed by polyacrylamide gel electrophoresis
[62] followed by Coomassie Blue or PageBlue™ (Thermo
Scientific) staining, or by Western blotting of electrotrans-
fered protein to Immobilon-P membranes as described
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previously [63]. Membranes were saturated in TBS-T
containing 5% dry milk and incubated with primary
antibodies including the rabbit anti-hexon fragment
antibodies produced here, the rabbit anti-pIIIa antibodies
(kindly provided by P. Hearing, School of Medicine, Stony
Brook, USA) [64] (both 1:1000), and the mouse monoclo-
nal anti-actin antibody (5A7 biorbyt UK), anti-GAPDH
antibody (MA5-15738, Thermo Scientific), and anti-tubulin
antibody (DM1A, Sigma) (all at 1 μg/ml). Incubation with
secondary antibodies included HRP-conjugated donkey
anti-rabbit IgG, sheep anti-mouse IgG (GE Healthcare,
both 1:4000), and sheep anti-dog IgG (GE Healthcare)
for 1 h. The immunoreactivity was determined using
the Luminata Crescendo Western HRP substrate
(Millipore) and scored using the ImageQuant LAS
4000 imager (GE Healthcare).
Immunofluorescence imaging
1 × 104 human A549 or mouse 3T6 cells were seeded in
50 μl of DMEM-FCS medium and were incubated at
37 °C for 3 h. The cells were then infected with virus
using an MOI of 1 for HAdV-B3-pIX-FS2A-eGFP, or al-
ternatively, 100 geq vp per cell for MAdV-1-ΔE1A-eGFP
and MAdV-2-ΔE1A-eGFP. The replication-competent
human virus gave rise to a strong GFP signals and cells
were incubated for 1 day, whereas the mouse cells were
incubated for 5 days, due to the weaker GFP signals pro-
duced by these viruses. The cells were fixed using 3%
PFA for 15 min at room temperature. The cells were
washed three times with PBS-N3 and quenched for
10 min at room temperature with PBS-N3 + 25 mM
NH4Cl. The cells were washed again three times and
blocked for 1 h at room temperature in PBS-N3 + 0.5%
BSA. The cells were then incubated with primary anti-
bodies diluted 1:500 in blocking buffer for one hour at
4 °C, washed three times and incubated with secondary
antibodies for 1 h at room temperature. The cells were
washed and 50 μl of PBS-N3 + DAPI was added to the
wells at least 30 min prior to imaging. The cells were
then imaged at a 20× magnification using a ImageXpress
Micro XLS system.
Immunogold-labelled electron microscopy imaging
Staining and analyses by transmission microscopy
(TEM) was performed as described earlier [65]. In brief,
10 μl of concentrated CsCl-purified adenovirus solutions
were pipetted onto glow discharged TEM mesh grids.
Virus was left to adsorb for 1-2 min, excess buffer was
dried using a filter paper and grids were washed four
times for 1 min in 10 μl of PBS with 10% goat serum.
Grids were then incubated in 10 μl of primary antibody
diluted 1:50 in PBS with 1% goat serum for 30 min at
room temperature. This was followed by additional
washing four times for 1 min in PBS with 10% goat
serum and then incubation with 10 μl of 1:50 diluted
secondary colloidal 10 nm gold-conjugated antibodies
for 30 min at room temperature. Grids were washed
twice in PBS with 0.1% BSA, three times in PBS and
twice with deionized water for 1 min each. Virus was
counterstained with 3% uranyl acetate for 20-40 s and the
excess staining solution was drained with filter paper.
Grids were allowed to air dry and were then imaged using
a TEM FEI Tecnai G2 electron microscope. The 9C12
antibody included as primary antibody was developed by
Laurence Fayadat and Wiebe Olijve, and was obtained
from Developmental Studies Hybridoma Bank developed
under the auspices of the National Institute of Child
Health and Human Development and maintained by the
University of Iowa, Department of Biology, Iowa City, IA.
Results
Design and production of adenoviral hexon fragments
In the past, either purified virus or purified virus proteins
were used for immunization to generate hexon-specific
antibodies [44, 66]. Since in our hands, purified MAdVs
yields were lower compared to HAdVs and purification of
MAdV hexon protein from lysates of infected cells was
not efficient (not shown), we decided to produce recom-
binant hexon fragments containing HVRs to induce spe-
cific antibodies. To this end, hexon protein sequences
from recently described MAdV-2 [48] and −3 [49] were
aligned to MAdV-1 and other known hexon sequences
(Fig. 1a and Additional file 1: Figure S1). All seven HVRs
characteristic for the sequence diversity across different
adenoviral sequences [34–37] coincided with the highest
variable stretches in the MAdV sequences.
Based on the previously published crystal structure of
the trimeric form of the hexon protein (PDB ID: 3TG7)
we then mapped these regions to the structural model of
the HAdV-C5 hexon (Fig. 1b). We next designed adeno-
viral hexon fragments of about 20 kDa mass containing
the HVRs 1-6, plus small parts of conserved regions at
each end of the fragment to maximize the chances of
preserving the secondary structure (Fig. 1a, Additional
file 1: Figure S1 and Additional file 2: Table S1). In order
to exclude sequences possibly containing common
species- or genus-specific reactivity, and due to molecu-
lar size constraints, the HVR 7 was not included in the
designed fragment as there is a highly extended region
between the HVR 6 and 7.
Four HVRs 1-6 hexon fragments were generated
including those of HAdV-B3, HAdV-C5, MAdV-1 and
MAdV-2. The HAdV-C5 fragment was included as con-
trol to check for blocking capacities of such fragments
(see below). The HAdV-B3 fragment and production of
HAdV-B3 hexon antibodies was included to characterize
HAdV-B3-derived vectors (L. Studer manuscript in
preparation and [67]). All fragments were expressed in
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E.coli BL21-CodonPlus(DE3)-RIPL cells as N-terminal
GST-fusion proteins containing a PreScission protease
cleavage site, that allowed efficient enzymatic removal of
the tag.
A three-step purification procedure was employed to
obtain highly pure hexon fragments (Fig. 2a). The first
step was affinity purification using Glutathione-Sepharose
beads. The GST-tagged protein bound to the affinity beads
and could be separated from the majority of the contami-
nants. The GST-fusion hexon fragments as well as the
final hexon fragments had a slightly slower mobility in
SDS-PAGE than expected (Additional file 3: Figure S2A,
Fig. 2b-e), which could be due to their relatively high
negative charge (pI ~4-5) [68]. The eluted protein was
treated with PreScission protease to cleave the GST-tag.
The second purification step consisted of an ion ex-
change separation on a Mono Q column which allowed to
separate the cleaved hexon fragment from the GST tag.
Apart from the HAdV-5 hexon fragment, the untagged
hexon protein fragments were found in the flow through
fraction, while the majority of the GST bound to the
column (Additional file 2: Figure S2B). For the third puri-
fication step the Mono Q peak fractions were pooled and
loaded on a second ion exchange Q5 column. All of the
four fragments bound to the column and, after applying a
KCl gradient, the hexon fragments were eluted revealing
variable elution conditions (Additional file 3: Figure S2C).
The purified protein fractions were briefly incubated with
a small amount of Glutathione-Sepharose beads to bind
residual GST and concentrate the hexon fragments. SDS-
PAGE analysis revealed highly pure ≥90% hexon protein
preparations (Fig. 2b-e). Apart from the MAdV-2
fragment, all other hexon fragments migrated as a double
band, either after Q5 elution or after concentration. Mass-
spectrometry analysis confirmed the identity of both
bands, although the cause of the differential migration
remained unclear. Possible reasons for heterogeneity are
degradation, oxidation or post-translational modifications.
(See figure on previous page.)
Fig. 1 Alignment of partial adenovirus hexon sequences and hexon protein trimer structure. a Sequence alignment of 19 adenovirus hexon sequences
containing HVRs 1-6. Protein sequences were obtained from GenBank and the alignment was performed using the MUSCLE algorithm. The color intensity
indicates how highly an amino acid in a particular position is conserved amongst species. Highly conserved epitopes are highlighted in dark blue while
variable epitopes are white or light blue. The HVRs 1-6 are highlighted by red bars and the cloned hexon fragments are highlighted by a blue bar. Hexon
N- and C-terminal ends were omitted (for alignment of full-length hexon sequences see Additional file 1: Figure S1). b Graphical representation of the
HAdV-C5 hexon protein trimer structure (PDB ID: 3TG7), side and top view. The HVRs 1-6 are highlighted in red and HVR 7 is highlighted in green
Fig. 2 Purification of recombinant adenoviral hexon fragments. a Schematic representation of the purification process. Transformed E.coli
BL21-CodonPlus(DE3)-RIPL cells were lysed to release cellular contents. The recombinant GST-fusion proteins were pulled down using
Glutathione-Sepharose beads. After elution, the GST tag was cleaved and the hexon fragments were further purified using Mono Q and
Q5 ion exchange chromatography. The resulting protein fractions were concentrated. b-e SDS-PAGE analyses of 1, 2 and 4 μl of purified
HAdV-B3, HAdV-C5, MAdV-1 and MAdV-2 hexon fragments. Arrows indicate the bands of the purified proteins
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It is difficult to ascertain the effect of this second band on
immunisation. We believe that even if the other band
were a slightly shortened product, most of the HVR epi-
topes should still be present and yield specific antibodies
after immunisation. In the animal, professional antigen
presenting cells process complex antigens into small pep-
tide fragments and present these fragments on their sur-
face which gives rise to the expansion of T-cells and
eventually B-cells, giving rise to a systemic humoral im-
mune response, including the production of immunoglob-
ulins, which are of particular interest in this study.
In summary, our three-step purification procedure
starting from a 4-l bacterial culture gave rise to highly
pure hexon fragments with overall protein yields ranging
from 600 to 850 μg. This material was further used for
functional analysis and immunization of rabbits to raise
polyclonal antibodies.
The HAdV-C5 HVRs 1-6 hexon fragment blocks the
neutralizing activity of a polyclonal antibody
We tested whether the hexon fragment was able to bind
HAdV-C5 neutralizing anti-hexon antibodies. If this were
the case, it could improve the production of native hexon-
recognizing antibodies. We evaluated the blocking activity
of one of the generated fragments, the HAdV-C5 hexon
fragment in a neutralization assay using a dog anti-HAdV-
C5 neutralizing serum [60, 61]. As expected, the dog anti-
HAdV-C5 serum stained various viral proteins including a
protein corresponding in size to hexon (Additional file 4:
Figure S3). We first tested the neutralization capacity of
the dog serum against HAdV-C5-CMVLuc. When
HAdV-C5-CMVLuc was pre-incubated with five-fold
dilutions of the dog sera, the dog sera potently blocked
expression mediated by HAdV-C5-CMVLuc in human
A549 cells (Fig. 3a). The same serum did not block
a b
c d
e f
Fig. 3 HAdV-C5 HVRs 1-6 hexon fragment efficiently blocks the neutralizing activity of an anti HAdV-C5 antibody. a, b Titration of the HAdV-C5
neutralizing serum. Five-fold serial dilutions of the neutralizing serum were pre-incubated with either HAdV-C5-CMVLuc or HAdV-B3-CMVLuc for
30 min before adding to human A549 cells. Luciferase activity was determined as relative light unit signal (RLU) in lysed cells 24 h post infection.
c-f Blocking of HAdV-C5 neutralizing activity by the HAdV-C5 HVRs 1-6 hexon fragment. Two neutralizing antibody dilutions, 1:250 and 1:1250, which gave
rise to <0.075% and ~5% residual HAdV-C5 activity, respectively, were used to repeat the neutralization assays in the presence of increasing amounts of
hexon fragment. Blocking of neutralization could be seen in the homologous system using HAdV-C5-CMVLuc, but not in the heterologous system for
HAdV-B3-CMVLuc-mediated expression
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HAdV-B3-CMVLuc-mediated expression (Fig. 3b), con-
firming the neutralization specificity of the dog serum. A
reduced luciferase activity effect of the dog serum at the
1:50 dilution against HAdV-B3-CMVLuc was obtained,
but it was considered to be unspecific due to cytopathic
effects observed on the cells, which resulted in a lower lu-
ciferase signal due to the reduced cell count. A possible
reason for the cell cytopathic effect includes the presence
of Thimerosal added as preservative to the sera, amount-
ing at the 1:50 dilution to concentrations that had been
reported to be toxic for human and mouse cells [69].
To test if the HAdV-C5 HVRs 1-6 hexon fragment
acted as an antibody decoy, we repeated the neutralization
assays in the presence of the hexon fragment. We used
two neutralizing antibody dilutions, 1:250 and 1:1250,
which previously had shown to gave rise to <0.075% and
~ 5% residual HAdV-C5 infection, respectively (Fig. 3a).
Addition of increasing amounts of the hexon fragment
increased the luciferase signal of HAdV-C5-CMVLuc, but
not of HAdV-B3-CMVLuc-mediated expression (Fig. 3c-f).
At the highest concentration of the HAdV-C5 HVRs 1-6
hexon fragment, blocking of the neutralizing activity was
almost complete for both serum dilutions, suggesting that
the dog serum did contain mainly hexon directed neutral-
izing antibodies. In summary, these data indicated that the
HAdV-C5 HVRs 1-6 hexon fragment existed in a quasi
native structure that sequestered and blocked virus-
neutralizing antibodies.
Hexon fragment antibodies reveal cross-reactivity and
bind to full-length hexon protein in immunoblot assays
The purified HAdV-B3, MAdV-1 and MAdV-2 HVRs 1-6
hexon fragments were used to produce hyperimmune sera
in rabbits. The resulting sera, hereafter referred to as
HAdV-B3- / MAdV-1- / MAdV-2-hexon antibody (Ab),
were tested in several assays to examine their properties.
To test the specificity of the generated antibodies, we
performed immunoblot assays using lysates from cells
infected with thirteen human and three mouse viruses.
Human HeLa cells were infected with HAdVs represent-
ing four species and included HAdV-B3, HAdV-B7,
HAdV-B16 and HAdV-B21 of the B1 subspecies, HAdV-
B11, HAdV-B14, HAdV-B34 and HAdV-B35 of the B2
subspecies, HAdV-D8, HAdV-D30 and HAdV-D37 of the
D species, and HAdV-C5 and HAdV-E4 from the C and E
species, respectively. Mouse CMT93 cells were infected
with all three known MAdVs. In addition to the hexon
antibodies, all blots were also immunostained using a
HAdV cross-reactive anti-pIIIa antibody [64] to check for
efficient infection, and an actin antibody to check for
sample loading. pIIIa is a conserved structural protein
contributing to capsid structure and stability. In our
experiments, it serves as loading control and a marker for
production of late transcribed genes, including hexon.
The HAdV-B3 hexon Ab strongly bound to the full-
length HAdV-B3 hexon, and also cross-reacted strongly
with most of the other hexons of the B1 and B2 subspecies
viruses, and with the hexons of the D serotypes included
here (Fig. 4a). Of note, weak signals of HAdV-B14 and
B34 of B2 subspecies were paralleled by relative weak pIIIa
signals, whereas pIIIa signals of all D serotypes were rather
robust. Hexons from HAdV-C5 and HAdV-E4, as well as
HAdV-B16 revealed weak binding and cross-reactivity.
When testing the MAdV-1 hexon Ab in a first experi-
ment with mouse CMT93 lysates harvested 72 h post in-
fection, it bound strongly to the MAdV-1 full-length
hexon, and weakly to the MAdV-3 hexon, which are
highly related in sequence [48] (Fig. 4b). In addition, the
MAdV-1 hexon Ab exhibited low affinity towards the
HAdV-B11 and HAdV-B35 hexon. The MAdV-2 hexon
Ab displayed low cross-reactivity to MAdV-1 hexon, but
strongly bound to the MAdV-2 full length hexon (Fig. 4c).
It was also noticed that the cross-reactive anti-pIIIa anti-
body did not efficiently recognize pIIIa from MAdVs
which could be explained by the low sequence similarity
to human adenoviruses in certain segments of the protein
[20]. Further, in contrast to cell lysates obtained from
HAdV infections, the actin signal in mouse cells infected
with MAdVs faded in the course of infection.
We repeated the infection experiment using an about
5-fold higher virus input followed by harvesting cell
lysates 48, 72 and 96 h post infection. In addition to
immunoblotting analyses, the cell lysates were also ana-
lyzed for protein levels by PageBlue staining (Fig. 4d).
Surprisingly, all MAdV-infected lysates revealed a robust
reduction in cell protein contents at all three time points
analyzed, when compared to uninfected cells. When im-
munostaining for GAPDH, weak signals were seen for
MAdV-1 and -3 only at 48 h post infection Staining for
actin and tubulin showed similar results (not shown), in
agreement with the reduced levels of cellular proteins.
In this experiment with higher virus input, the MAdV-1
hexon Ab bound to similar extents to MAdV-1 and
MAdV-3 full-length hexon proteins. The MAdV-2
hexon Ab displayed low cross-reactivity to MAdV-1 as
well as to MAdV-3 hexon protein.
In summary, all three sera produced against hexon
HVRs 1-6 fragments revealed binding to homologous
full-length hexon protein demonstrating variable degrees
of cross-reactivity to heterologous hexons when tested
for binding in immunoblot assays representing mostly
non-native forms of hexons.
HAdV-B3- and MAdV-2- but not MAdV-1-hexon fragment
antibodies display hexon signals in IF analysis of infected
cells and in immuno-EM of intact virions
Immunofluorescence (IF) microscopy is widely used to
study the infectious life cycle of viruses. To investigate
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whether the hexon fragment antibodies were suitable for
use in IF, human and mouse cells were infected with eGFP
expressing reporter viruses followed by analysis for eGPF
and hexon signals. When human A549 cells were infected
with replication-competent HAdV-B3-pIX-FS2A-eGFP
we were able to observe a strong hexon signal that over-
lapped with the GFP signals (Fig. 5a). Of note, uninfected
cells revealed a weak background signal when using the
HAdV-B3 hexon Ab. Similarly, when mouse 3T6 cells
were infected with recombinant MAdV-2-ΔE1A-eGFP,
hexon and GFP signals coincided to a large degree,
whereas uninfected cells revealed a very low background
staining with the MAdV-2 hexon Ab (Fig. 5b). In contrast,
when 3T6 cells infected with MAdV-1-ΔE1A-eGFP virus
were stained with the MAdV-1 hexon Ab, a high back-
ground was observed with signals that did not overlap
with the GFP signals (Fig. 5c).
These findings were corroborated when the same anti-
bodies were used for staining of CsCl-purified viruses by
high-resolution immunogold EM. For this, wild type
HAdV-B3, HAdV-C5, MAdV-1 and -2 were first incu-
bated with the three hexon-fragment antibodies or with
the mouse monoclonal 9C12 antibody specifically bind-
ing to HAdV-C5 [59], followed by incubation with gold-
labeled secondary antibodies (Fig. 6). When staining
HAdV-C5 with the 9C12 antibody, we observed multiple
gold grains on the HAdV-5 capsid surface. This staining
was specific, since none of the other virus capsids were
bound by the 9C12 antibody. Gold grains were also seen
when HAdV-B3 was incubated with the HAdV-B3
hexon Ab, or MAdV-2 was incubated with the MAdV-2
hexon Ab, albeit at lower numbers than for 9C12. In
contrast, in the case of MAdV-1 we were not able to de-
tect immune-gold particles on the intact viral capsids. In
summary, our IF and EM results suggest that HAdV-B3
and MAdV-2 hexon Abs recognized in addition to non-
native also native forms of hexon, whereas the MAdV-1
hexon HVRs 1-6 antibodies recognized only non-native
hexon forms.
HAdV-B3- and MAdV-1-hexon Abs exhibit no neutralizing
activity on virus infection
Since two of our hexon Abs recognized native hexon
forms, we tested if they also had neutralizing activity. To
test this we repeated the neutralizing assays using
HAdV-B3-CMV-Luc and MAdV-1-E1A-FS2A-GL for
infection of human and mouse cells, respectively. When
compared to the pre-immune sera, neither the HAdV-B3
hexon Ab (Fig. 7a) nor the MAdV-1 hexon Ab (Fig. 7b)
revealed any neutralizing activity. As seen previously with
the dog anti-HAdV-C5 serum, a small cytopathic effect
induced reduction of luciferase expression at the 1:50 dilu-
tion of both sera. When including as positive control a
hyperimmune rabbit anti-HAdV-B3 serum, HAdV-B3-
CMV-Luc-mediated luciferase expression was strongly
blocked (Fig. 7c). The neutralizing activity of the MAdV-2
hexon Ab could not be tested here, due to the lack of a
MAdV-2 luciferase reporter virus.
a
b
c
d
Fig. 4 Antibodies raised against hexon fragments reveal variable cross-
reactivity against hexon proteins in Western immunoblotting. Lysates
from HeLa cells infected with thirteen HAdVs representing the four
species B, C, D and E and CMT93 lysates with all three different MAdVs
were analyzed. Uninfected HeLa or CMT93 cells were included as
negative controls, respectively. The blots were stained with the
HAdV-B3 hexon Ab (a), the MAdV-1 hexon Ab (b), or the MAdV-2
hexon Ab (c). In addition, all blots were immunostained using a
(HAdV) cross-reactive anti-pIIIa antibody to check for efficient infection,
and an actin antibody for loading control. It was noticed that the actin
signal in mouse cells infected with MAdVs strongly faded in the course
of infection. d A second set of CMT93 cells infected with all three
MAdVs at about five-fold higher virus input were harvested 48, 72 and
96 h post infection. The blot was immunostained using the MAdV-1
and MAdV-2 hexon Ab and GAPDH loading control antibody. The same
lysates were stained for protein content using PageBlue. Marker proteins
of 118, 85, 48, 34, 26 and 20 kDa were included in the first lane
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Discussion
Standard procedures to generate adenovirus hexon-specific
antibodies include preparations of purified virions, or viral
proteins for the purpose of immunization [44, 66]. How-
ever, not all adenoviruses can be amplified efficiently in cell
culture. For instance the two HAdVs belonging to species
F (HAdV-F40 and −41) are notoriously difficult to grow to
high titers [70]. When trying to isolate MAdV-1 and-2
hexon protein from infected cell cultures using standard
protocols [71] we failed to obtain purified proteins. Since
hexon is a large protein of 108 kDa that requires a viral
chaperone activity [72], production in E.coli was found to
be inefficient (unpublished data).
We decided to generate a small hexon subfragment
consisting of about one fifth of the full-length size, but
still containing six of the seven HVRs (Fig. 1a, Additional
a
b
c
Fig. 5 Use of hexon fragment antibodies in immunofluorescence analysis of GFP-reporter virus infected cells. a Human A549 cells were infected
with replication-competent HAdV-3-pIX-FS2A-eGFP at an MOI of 1 and cells were fixed and stained one day post infection with the HAdV-B3
hexon Ab. Co-localization of a HAdV-B3 hexon specific signal with the GFP signal was observed in the overlays. b Mouse 3T6 cells were infected
with 100 geq vp of MAdV-2-ΔE1A-eGFP and cells were fixed and stained five days post infection with the MAdV-2 hexon Ab. Co-localization of
the MAdV-2 hexon signal with GFP was observed in channel overlays. c Mouse 3T6 cells were infected with 100 geq vp of MAdV-1-ΔE1A-eGFP
and cells were fixed and stained five days post infection with the MAdV-1 hexon Ab. No co-localization of GFP and hexon signal was observed.
DAPI staining is highlighted in blue, the GFP signal is highlighted in green and the hexon antibody signal is highlighted in red
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file 1: Figure S1 and Additional file 2: Table S1). HVR 7
was omitted since inclusion of this region increases the
fragment size by about two-fold. In addition, neutralization
profile analysis of hexon chimeric HAdV-C5 containing ei-
ther HVRs 1-7 or only HVRs 1-6 of HAdV-C2 as well as
epitope mapping of chimpanzee Ad68 hexon using a panel
of neutralizing antibodies had suggested that most reactiv-
ity was contained in the HVRs 1-6 sequence [27, 38]. Simi-
lar data were also reported with HAdV-B3 and -B7 [73,
74]. In contrast, mapping of the epitope recognized by the
mouse monoclonal 9C12 anti-HAdV-C5 hexon antibody
suggested also a contribution of HVR 7 to binding of this
neutralizing hexon antibody [59, 75].
Following efficient expression in bacteria, our three-step
purification procedure of the hexon HVRs 1-6 fragments
using standard biochemical methods resulted in >90%
pure protein preparations based on SDS-PAGE analysis,
with sufficient quantities for immunization and produc-
tion of polyclonal antibodies in rabbits (Fig. 2). It was
somewhat surprising to find that the HAdV-C5 fragment
was almost completely blocking a dog-anti HAdV-C5
neutralizing activity although the fragment consisted only
of HVRs 1-6 (Fig. 3). Hexon fragment proteins consisting
of HVRs 1-7 have been used for similar blocking experi-
ments [42], as well as a HVR 5-derived small peptide of
HAdV-C5 [28]. However, blocking activity by peptides
may be rather exceptional, since it has been estimated that
only a small fraction of <10% of the antibodies directed
against native antigens bind to linear epitopes [76]. In the
case of HAdV-D48 hexon, neutralizing antibodies did not
recognize linear peptides [34]. Whether all of the four
hexon fragments are capable of blocking neutralizing anti-
bodies remains to be determined once the recombinant
reporter viruses are available.
Fig. 6 Transmission electron microscope analysis of immunogold-
labeled viral capsids. Purified HAdV-B3, HAdV-C5, MAdV-1 and MAdV-2
were first incubated with the indicated rabbit hexon antibodies for
HAdV-B3, MAdV-1, MAdV-2, or the monoclonal mouse 9C12 antibody
specific for HAdV-C5, respectively. Following staining with colloidal
10 nm gold-labeled anti-rabbit or anti-mouse antibodies, uranyl-
acetate staining was performed. TEM images were acquired at
135 000× magnification
a
b
c
Fig. 7 HAdV-B3 and MAdV-1 hexon Abs do not reveal neutralizing
activity. a Five-fold serial dilutions of preimmune serum or HAdV-B3
hexon Ab were pre-incubated with HAdV-B3-CMVLuc for 30 min
before adding to human A549 cells. b Five-fold serial dilutions of
preimmune serum or MAdV-1 hexon Ab were pre-incubated with
MAdV-1-E1A-FS2A-GL for 30 min before adding to mouse CMT93
cells. For both viruses, luciferase activity was measured as RLU in
lysed cells 24 h post infection. c Comparison of the neutralizing
activities of the HAdV-3 hexon Ab with a neutralizing rabbit anti
HAdV-B3 serum. Dilutions and experimental set-up were as
described above
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Hexon antigenic determinants and antibodies raised
against hexon will not only be influenced by the nature
of antigen used for immunization, e.g., purified virus, or
hexon or partial fragment, but also by the immunization
procedure which can include use of alum precipitation,
adjuvants, and terminal boost with virus only. Thus,
generation of mouse monoclonal antibodies resulted in
cross-reactive genus-, species- or type-specific antibodies
[44, 66]. Type-specific and neutralizing epitopes have
been suggested to be conformation dependent [27, 34],
whereas non-neutralizing and cross-reactive hexon anti-
bodies with common species- and genus-specific reactiv-
ity have been suggested to recognize sites that are
accessible on the purified hexon but partially masked in
the intact virion and outside of the HVRs [27, 44, 45].
A variable degree of cross-reactivity binding to heterol-
ogous hexons was observed when testing our three hexon
Abs for binding in immunoblot assays, representing bind-
ing to mostly non-native forms of hexons. In the case of
the HAdV-B3 hexon Ab, extensive cross-reactivity with
most of the other tested hexons of the B1 and B2 subspe-
cies viruses, and with the hexons of the D types were no-
ticed (Fig. 4a). The observed cross-reactivity between
species B and D is confirmed by phylogenetic tree analyses
data of conserved and variable hexon regions, revealing that
the B and D species viruses are more closely related than
the B and C species viruses [77]. The reduced cross-
reactivity to hexon of HAdV-B16 is in line with the previ-
ously noted clustering of the HAdV-B16 hexon sequence to
the HAdV-E4 sequence, suggested to have resulted from a
recombination between sequences of these viruses [77, 78].
Since the MAdVs clade is rather distant from the other
Mastadenovirus clades [48], it is not surprising to find
lower levels of cross-reactivity of the MAdV-1 hexon anti-
bodies and almost no cross-reactivity with the MAdV-2
hexon antibodies (Fig. 4b, c). The MAdV-1 hexon directed
antibodies bound stronger to the MAdV-3 hexon than to
the MAdV-2 hexon, reflecting the closer ancestor relation-
ship of MAdV-1 and -3 compared to MAdV-2 [48].
When used for detection of hexon proteins in IF of in-
fected cells and for EM of purified virus, the HAdV-B3
and MAdV-2 hexon antibodies, but not the MAdV-1
antibody bound native hexon proteins (Figs. 5 and 6).
However, when used for virus neutralizing assays, neither
the HAdV-B3 nor the MAdV-1 antibodies revealed any
blocking effect (Fig. 7), suggesting that the MAdV-1
antibody exclusively detects nonnative and denatured epi-
topes, whereas the HAdV-B3 antibody recognizes native
hexon epitopes to some degree, but not those epitopes
contained on trimeric hexons leading to neutralization.
Our results with the HAdV-B3 hexon antibody is in
contrast to a study by Yuan et al. which generated
HAdV-B3 neutralizing antibodies immunizing with vari-
ous short HVR peptides bound to KLH carrier protein
[43]. However, the Yuan et al. study did not include
other virus serotypes to confirm the specificity. Previous
studies have shown that not all hexon binding antibodies
exert neutralizing activity, but those that do bind with
high affinity and function by rapid, single-hit kinetics,
acting at a post-entry and TRIM21-dependent step [18,
27, 79, 80]. Non-neutralizing antibodies were found to
bind with lower avidity to native hexon than neutralizing
antibodies [27], which could explain why two of our
three hexon antibodies still bound to intact virus in EM
analysis, despite their lack of neutralization.
Conclusions
The procedure described here can be applied to generate
monoclonal or polyclonal antibodies against adenovi-
ruses that are difficult to grow in cell culture. Such anti-
bodies can greatly speed up the process of optimizing
the cultivation and purification conditions of the virus,
and enhance studies of the infection cycle and serve as
diagnostic tools in tissue analyses. Purified hexon frag-
ments can be used in a variety of biochemical assays
apart from immunizing animals, for instance blocking
neutralization assays, pull-down assays or competition
assays. The method described here is cost effective and
yields milligram quantities of recombinant soluble hexon
protein. It extends traditional methods, and improves
adenoviral research and diagnostics.
Additional files
Additional file 1: Figure S1. Protein sequence alignment of 19 full-
length adenoviral hexon proteins. Protein sequences were obtained from
GenBank and the alignment was performed using the MUSCLE algorithm.
The HVRs1-6 are highlighted by red bars, HVR7 by a green bar and the
cloned hexon fragment is highlighted by a blue bar. (PDF 795 kb)
Additional file 2: Table S1. Hexon fragment data and oligonucleotides
used for generation of expression constructs. (DOC 45 kb)
Additional file 3: Figure S2. Adenoviral HVRs 1-6 hexon fragment
purification. SDS-PAGE analyses of HVRs1-6 hexon fragments of HAdV-B3
HAdV-C5, MAdV-1 and -2 were performed after GSH affinity purification (A),
Mono Q ion-exchange purification (B), and Q5 ion-exchange purification (C).
The Flow fraction represents proteins that did not bind to the
chromatography matrix, the Wash fraction represents proteins washed out
during the washing step of the purification, and the Beads fraction represents
proteins that were eluted from the matrix by SDS boiling. Elution from the
Q5 ion-exchange column was performed applying a slow KCl gradient of 50-
600 mM. The hexon fragments were eluted at different KCl concentrations,
including 150-210 mM KCl for the HAdV-B3 fragment, 270-350 mM KCl for
the HAdV-C5 fragment, 90-130 mM KCl for the MAdV-1 ragment and 60-
110 mM KCl for the MAdV-2 fragment. (PDF 2150 kb)
Additional file 4: Figure S3. Immunostaining of hexon by the
neutralizing dog anti-HAdV-C5 serum. Lysates from uninfected and infected
Hela cells were analyzed by Western immunoblot using the polyclonal dog
anti-HAdV-C5 serum. Several viral proteins including a protein corresponding
in relative size to hexon (108 kDa) were detected. (PDF 346 kb)
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